Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.
作者信息
Madan Sumit, Kyle Robert A, Greipp Philip R
出版信息
Mayo Clin Proc. 2010 Mar;85(3):300. doi: 10.4065/mcp.2009.0653.
Abstract
摘要
相似文献
1
Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.
Mayo Clin Proc. 2010 Mar;85(3):300. doi: 10.4065/mcp.2009.0653.
2
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
Clin Cancer Res. 2011 Apr 1;17(7):1692-700. doi: 10.1158/1078-0432.CCR-10-1066. Epub 2011 Feb 16.
3
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
N Engl J Med. 2007 Jun 21;356(25):2582-90. doi: 10.1056/NEJMoa070389.
4
5
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Hematology Am Soc Hematol Educ Program. 2005:340-5. doi: 10.1182/asheducation-2005.1.340.
6
Genomic analysis of high-risk smoldering multiple myeloma.
Haematologica. 2012 Sep;97(9):1439-43. doi: 10.3324/haematol.2011.060780. Epub 2012 Feb 13.
7
["Benign" monoclonal gammopathy: prognostic value of initial bone marrow study].
Sangre (Barc). 1985;30(3):308-19.
8
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Cancer. 2012 Nov 15;118(22):5544-9. doi: 10.1002/cncr.27657. Epub 2012 Jul 11.
9
Using aspirates for multiple myeloma research probably excludes important data.
Br J Haematol. 2006 Jul;134(2):245-6. doi: 10.1111/j.1365-2141.2006.06160.x.
10
Unusual morphologic presentation of plasma cells during the course of a multiple myeloma.
Haematologica. 2004 Apr;89(4):EIM04.
引用本文的文献
1
Smoldering multiple myeloma: Integrating biology and risk into management.
Semin Hematol. 2025 Feb;62(1):3-10. doi: 10.1053/j.seminhematol.2024.10.002. Epub 2024 Oct 18.
2
How to Identify and Manage High-Risk Smoldering Multiple Myeloma.
Curr Oncol Rep. 2024 Nov;26(11):1398-1409. doi: 10.1007/s11912-024-01596-5. Epub 2024 Aug 23.
3
Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms.
Int J Mol Sci. 2021 Apr 9;22(8):3895. doi: 10.3390/ijms22083895.
4
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Nat Commun. 2021 Jan 12;12(1):293. doi: 10.1038/s41467-020-20524-2.
5
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Blood Adv. 2020 May 26;4(10):2236-2244. doi: 10.1182/bloodadvances.2019001275.
6
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.
7
Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
Haematologica. 2018 Jul;103(7):1229-1234. doi: 10.3324/haematol.2018.189985. Epub 2018 Apr 19.
8
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Haematologica. 2015 Sep;100(9):1214-21. doi: 10.3324/haematol.2015.124651. Epub 2015 May 28.
9
Smoldering multiple myeloma.
Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2.
10
Dilemmas in treating smoldering multiple myeloma.
J Clin Oncol. 2015 Jan 1;33(1):115-23. doi: 10.1200/JCO.2014.56.4351. Epub 2014 Nov 24.
本文引用的文献
1
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
N Engl J Med. 2007 Jun 21;356(25):2582-90. doi: 10.1056/NEJMoa070389.
2
Plasma cell labeling index.
Methods Mol Med. 2005;113:25-35. doi: 10.1385/1-59259-916-8:25.
3
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
Br J Haematol. 2003 Jun;121(5):749-57.
Zotero 插件